Jian Zhou1, Zuraidah Sulaiman2, Ryan M Llorin3, Kim-Hor Hee4, Lawrence Soon-U Lee4, David C Lye5, Dale A Fisher6, Vincent H Tam7. 1. Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, TX, USA. 2. Department of Medicine, National University Hospital, Singapore. 3. Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore. 4. Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 5. Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 6. Department of Medicine, National University Hospital, Singapore Yong Loo Lin School of Medicine, National University of Singapore, Singapore. 7. Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, TX, USA Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, TX, USA vtam@uh.edu.
Abstract
OBJECTIVES: Ertapenem is a broad-spectrum carbapenem antibiotic used to treat severe bacterial infections. In view of its dosing convenience, it is increasingly used as outpatient therapy. The objective of this study was to determine the pharmacokinetics and renal disposition of ertapenem in outpatients with complicated urinary tract infections. METHODS: Ertapenem was administered as a daily intravenous infusion of 1 g over 30 min. At steady-state, blood and urine samples were collected over one dosing interval. Drug concentrations in serum and urine were determined using a validated liquid chromatography-tandem mass spectrometry method. A population pharmacokinetic model was used to characterize ertapenem serum and urine profiles. The likelihood of the standard dosing achieving a favourable pharmacokinetic-pharmacodynamic exposure was evaluated using Monte Carlo simulations. RESULTS: Ten adult male patients were studied. Concentration-time profiles of ertapenem in both serum (r(2) =0.997) and urine (r(2) =0.982) were captured satisfactorily. Mean values for volume of distribution, clearance and elimination t½ were 4.8 L, 0.7 L/h and 6.1 h, respectively. A high ertapenem concentration (>128 mg/L) could be attained in the urine at 40% of the dosing interval. CONCLUSIONS: The pharmacokinetics of ertapenem in serum and urine were characterized. Our simulations suggested that a sufficiently high ertapenem concentration could be achieved in urine to overcome low to intermediate resistance. Clinical investigations to validate our findings are warranted.
OBJECTIVES:Ertapenem is a broad-spectrum carbapenem antibiotic used to treat severe bacterial infections. In view of its dosing convenience, it is increasingly used as outpatient therapy. The objective of this study was to determine the pharmacokinetics and renal disposition of ertapenem in outpatients with complicated urinary tract infections. METHODS:Ertapenem was administered as a daily intravenous infusion of 1 g over 30 min. At steady-state, blood and urine samples were collected over one dosing interval. Drug concentrations in serum and urine were determined using a validated liquid chromatography-tandem mass spectrometry method. A population pharmacokinetic model was used to characterize ertapenem serum and urine profiles. The likelihood of the standard dosing achieving a favourable pharmacokinetic-pharmacodynamic exposure was evaluated using Monte Carlo simulations. RESULTS: Ten adult male patients were studied. Concentration-time profiles of ertapenem in both serum (r(2) =0.997) and urine (r(2) =0.982) were captured satisfactorily. Mean values for volume of distribution, clearance and elimination t½ were 4.8 L, 0.7 L/h and 6.1 h, respectively. A high ertapenem concentration (>128 mg/L) could be attained in the urine at 40% of the dosing interval. CONCLUSIONS: The pharmacokinetics of ertapenem in serum and urine were characterized. Our simulations suggested that a sufficiently high ertapenem concentration could be achieved in urine to overcome low to intermediate resistance. Clinical investigations to validate our findings are warranted.
Authors: J C Bader; E A Lakota; G E Dale; H S Sader; J H Rex; P G Ambrose; S M Bhavnani Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: Daniel T Anderson; Benjamin Albrecht; K Ashley Jones; Jesse T Jacob; Mary Elizabeth Sexton; Zanthia Wiley; William C Dube; Benjamin Lee; Sujit Suchindran Journal: Open Forum Infect Dis Date: 2022-02-14 Impact factor: 3.835
Authors: Joe S Smith; David J Borts; Clare C Slagel; Suzanne M Rajewski; Alain Bousquet-Melou; Aude A Ferran; Paul J Plummer; Jon P Mochel Journal: Comp Med Date: 2019-10-03 Impact factor: 0.982
Authors: Belén Gutiérrez-Gutiérrez; Elena Pérez-Nadales; Salvador Pérez-Galera; Mario Fernández-Ruiz; Jordi Carratalà; Isabel Oriol; Elisa Cordero; José Antonio Lepe; Ban Hock Tan; Laura Corbella; Mical Paul; Alejandra M Natera; Miruna D David; Miguel Montejo; Ranganathan N Iyer; Ligia Camera Pierrotti; Esperanza Merino; Seema Mehta Steinke; Meenakshi M Rana; Patricia Muñoz; Alessandra Mularoni; Christian van Delden; Paolo Antonio Grossi; Elena María Seminari; Filiz Gunseren; Erika D Lease; Emmanuel Roilides; Jesús Fortún; Hande Arslan; Julien Coussement; Zeliha Koçak Tufan; Benoit Pilmis; Marco Rizzi; Belén Loeches; Britt Marie Eriksson; Edson Abdala; Fabio Soldani; Warren Lowman; Wanessa Trindade Clemente; Marta Bodro; María Carmen Fariñas; Esra Kazak; Luis Martínez-Martínez; José María Aguado; Julián Torre-Cisneros; Álvaro Pascual; Jesús Rodríguez-Baño Journal: Antimicrob Agents Chemother Date: 2021-08-09 Impact factor: 5.191
Authors: Arturo Ortiz-Álvarez; Mónica A Delgado-Ramírez; Montserrat Cuevas-Zúñiga; Teresa Hernández-Carrera; David Moncada Barrón; Daniel Aguilar Zapata; Rafael R Valdez Vázquez; Juan Pablo Ramírez-Hinojosa; Ana Patricia Rodríguez-Zulueta Journal: Infect Drug Resist Date: 2018-12-28 Impact factor: 4.003